Peter Anastasiou

Peter Anastasiou has over 30 years of work experience in the pharmaceutical and healthcare industry. Peter is currently serving as the Chief Executive Officer at Capsida Biotherapeutics since January 2022. Prior to that, they held various leadership roles at Lundbeck, including Executive Vice President and Head of North America, President of North America, Chief Commercial Officer for the U.S., and VP & General Manager for Psychiatry. Peter also served on the Board of Directors for PhRMA from July 2017 to December 2021. Additionally, Peter has been actively involved in philanthropic work and served on the Board of Directors for organizations such as Bear Necessities Pediatric Cancer Foundation. Peter has a strong background in marketing, having held positions as VP of Marketing at Neuronetics, Inc., and Marketing Director at Bristol-Myers Squibb. Peter started their career as a Global Marketing Manager at Eli Lilly.

Peter Anastasiou has an education history that includes a Bachelor of Arts degree in Economics and Management from Albion College. Peter also completed a Master of Business Administration (MBA) degree at Indiana University - Kelley School of Business. However, no specific start or end years are provided for either of these educational experiences.